Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 with Sintilimab and Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma
NCT06956716Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iNeo-Vac-R01 in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhejiang University. Started Apr 2025; status: recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06956716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956716.